Merck & Co., Inc.
MRKHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Merck & Co., Inc. focuses on Drug Manufacturers - General services and products. Merck & Co., Inc. operates as a healthcare company worldwide. Valued at $314.90B, MRK is a mega-cap name in its sector. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$314.90B
Beta
0.20
P/E (TTM)
36.02
P/E (Fwd)
13.20
EPS (TTM)
$3.54
EPS (Fwd)
$9.66
ROE
18.9%
ROA
12.6%
Cash
$5.70B
Total Debt
$49.12B
Free CF
$14.05B
52W Change
59.5%
Annual Financials
Cash vs Debt
Merck & Co., Inc. carries $49.12B in total debt against $5.70B in cash reserves — debt is roughly 8.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $14.05B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 18.9% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 12.6% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $59.28B (2022) to $65.01B (2025).
With a beta below 0.7, Merck & Co., Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Merck & Co., Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing MRK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.